

Secondary Trading Notice

Resonance Health Limited (“Company”) confirms that it has issued the 20,000,000 fully paid ordinary shares at nil consideration (Collateral Shares) to Acuity Capital Investment Management Pty Ltd (“Acuity Capital”) pursuant to the Controlled Placement Agreement (CPA) with Acuity Capital (see ASX announcement dated 30 April 2019).

The Collateral Shares were issued under the Company’s 15% placement capacity under Listing Rule 7.1 as outlined in the Appendix 3B announced on the ASX platform on 30 April 2019.

Secondary Trading Notice (the “Notice”) Pursuant to Paragraph 708A(5)(e) of the Corporations Act 2001 (the “Act”)

The Act restricts the on-sale of securities issued without disclosure, unless the sale is exempt under section 708 or 708A of the Act. By giving this notice, a sale of the Collateral Shares noted above will fall within exemption in section 708A(5) of the Act.

The Company hereby notifies ASX under paragraph 708A(5)(e) of the Act that:

- (a) The Company has issued the Shares without disclosure to investors under Part 6D.2 of the Act;
- (b) as at the date of this Notice, the Company has complied with provisions of Chapter 2M of the Act as they apply to the Company, and section 674 of the Act; and;
- (c) as at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act.

Yours faithfully,

Agha Shahzad Pervez
Company Secretary